Fotemustine and interferon à2b in metastatic malignant melanoma

Weichenthal, Michael; Möhr, Peter; Stephan, Ulrike; Altenhoff, J.; Kowalzick, L.; Marseille, A.; Sarkany, Marlis; Hossfeld, Dieter K.; Breitbart, Eckhard W.

doi:10.1007/s004320050134

Cited by 9 publications

(3 citation statements)

References 17 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it has alkylating and carbamoylating effects on nucleic acids (Hayes et al, 1997). Both effects may induce the expression of stress molecules such as hsp70 or MICA which can link chemo-and immunotherapy (Weichenthal et al, 1998). To this end, fotemustine, in combination with sequential immunotherapy for treatment of metastatic ocular melanoma, resulted in a median survival of one year (95% confidence interval 347 and 390 days); the overall survival of patients experiencing an objective benefit of this therapy in the form of an objective response or a stable disease was 19 months.…”

Section: Discussionmentioning

confidence: 99%

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2

et al. 2002

View full text Add to dashboard Cite

Malignant melanoma of the uvea is remarkable for purely haematogenous dissemination and its tendency to metastasise to the liver. Although the liver is involved in up to 95% of patients, 50% of these also develop extrahepatic metastases, most often in the lungs, bone, skin, and brain. The only effective treatments reported to date relied on hepatic arterial chemoembolisation or -perfusion. The objective of this study was to establish a therapy protocol addressing patients with both sole liver involvement and systemic disease. Forty-eight patients with metastatic ocular melanoma received fotemustine 100 mg m 72 either as 60-min infusion into the hepatic artery or as 15-min infusion via a peripheral vein, depending on the metastatic sites involved, i.e., restriction to the liver or hepatic together with extrahepatic disease. For the first treatment cycle this infusion was repeated after one week. For all cycles, subsequent to a three week resting period, patients received an immunotherapy consisting of subcutaneous interleukin 2 and interferon a 2 . Although objective responses were more frequent within the cohort receiving intraarterial fotemustine (21.7 vs 8%), this difference did not translate into a significant benefit in overall survival, i.e., 369 and 349 days, respectively. Of note, this overall survival is much longer than that repeatedly reported for stage IV uveal melanoma not treated with fotemustine, suggesting a therapeutic activity of this cytostatic drug even after systemic administration.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Adverse drug reactions are tolerable except lung toxicity 77 . RRs can also not be improved by combination of temozolomide and cisplatin or fotemustine and INF‐α 78,79 …”

Section: Resultsmentioning

confidence: 99%

“…77 RRs can also not be improved by combination of temozolomide and cisplatin or fotemustine and INF-α . 78,79 In summary, combinations of chemotherapeutic agents have not been proven superior to single-agent monochemotherapy with dacarbazine in randomized trials, and no meaningful effect on survival can be shown by any combination (Evidence level 1a).…”

Section: Polychemotherapiesmentioning

confidence: 99%

Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine

Nashan

Müller

Grabbe

et al. 2007

Acad Dermatol Venereol

View full text Add to dashboard Cite

Although the therapeutic efficacy is very limited, dacarbazine cannot be rejected as standard therapy for disseminated melanoma, because no other therapeutic regimen exhibits a survival benefit over DTIC in an evidence-based analysis. This lack of therapeutic progress over the past 40 years clearly calls for further clinical studies, and patients should be enrolled into clinical trials whenever possible.

show abstract

Development of a Syngenic Murine B16 Cell Line-Derived Melanoma Susceptible to Destruction by Neuroattenuated HSV-1

et al. 2001

View full text Add to dashboard Cite

HSV-1 ICP34.5 mutants can slow progression of preformed tumors in rodent models. However, the current models available for study are limited due to the lack of a syngenic, low-immunogenic tumor model susceptible to HSV-1. Thus we have developed a new model to determine the role of the immune response in viral-mediated tumor destruction. The human herpesvirus entry (Hve) receptors (HveA, HveB, and HveC) and a control plasmid were transfected into B78H1 murine melanoma cells. Transfection of HveA and HveC conferred sensitivity to HSV-1 to these cells. A10 (HveA), C10 (HveC), and control cells were able to form tumors reproducibly in vivo. The transfection of the receptors into B78H1 cells did not induce a detectable in vivo immunogenicity to the tumors. Finally, A10 and C10 tumor-bearing mice treated with HSV-1 1716 had significant prolongation of survival compared to mock-treated mice. These data suggest that A10 and C10 will be useful as in vivo models for studying the role of the immune response in viral-mediated tumor destruction.

show abstract

Fotemustine and interferon à2b in metastatic malignant melanoma

Cited by 9 publications

References 17 publications

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2

Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine

Development of a Syngenic Murine B16 Cell Line-Derived Melanoma Susceptible to Destruction by Neuroattenuated HSV-1

Contact Info

Product

Resources

About